Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants
|
|
- Vanessa Small
- 6 years ago
- Views:
Transcription
1 Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, a Regina Fölster-Holst, MD, b Peter Höger, MD, c Diamant Thacxi, MD, a Helena Löffler, MD, d Doris Staab, MD, e and Matthias Bräutigam, PhD, d for the CASM981CDE04-Study Group Frankfurt am Main, Kiel, Hamburg, Nürnberg, and Berlin, Germany Background: Data on the efficacy of pimecrolimus cream 1% within the first days of treatment are scarce, as in previous studies, the first postbaseline assessment was performed only after 1 week. Objective: We sought to investigate the onset of action of pimecrolimus cream 1% in infants with mild to very severe atopic eczema. Methods: We used pimecrolimus cream 1% (n = 129) or vehicle cream (n = 66) administered in a double-blind manner for 4 weeks and then open-label pimecrolimus cream 1% for 12 weeks, with a 4-week follow-up period. Results: Pimecrolimus cream 1% reduced the mean Eczema Area and Severity Index at 4 weeks by 71.5% compared with an increase of 19.4% with vehicle (P <.001). The reduction in the Eczema Area and Severity Index with pimecrolimus cream 1% was significant at day 4 (38.5% vs 17.6% increase with vehicle). Significant improvements in caregivers assessments of pruritus and sleep loss were observed with pimecrolimus cream 1% by day 2 (P <.03) and day 3 (P =.002), respectively, compared with vehicle. Responses to pimecrolimus cream 1% From a Johann Wolfgang Goethe-Universität, Hautklinik, Frankfurt am Main; b Christian-Albrechts-Universität, Hautklinik, Kiel; c the University of Hamburg, Department of Dermatology, Division of Paediatric Dermatology, Hamburg; d Novartis Pharma GmbH, Clinical Research, Nürnberg; and e Charite-Virchow Klinikum, Kinderklinik und Poliklinik, Berlin. Supported by Novartis Pharma GmbH. Conflict of interest statement: The following have a financial interest-relationship as follows. R. Kaufmann: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, and Versicor. D. Thacxi: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, Versicor; lecture honoraria from Novartis, Biogen, Fumedica, Hermal, Leo; consultant for Novartis and Fujisawa. R. Fölster-Holst: grant-research support from Novartis, Fujisawa, Hartmann and Stallergen; lecture honoraria from Novartis and Fujisawa; consultant for Novartis. P. Höger: grant-research support from Novartis; consultant for Novartis. D. Staab: grant-research support from Novartis and Fujisawa; lecture honoraria from Novartis. H. Löffler and M. Bräutigam are employees of Novartis Pharma GmbH. Received for publication May 11, 2004; revised August 6, 2004; accepted for publication August 6, Available online October 7, Reprint requests: Roland Kaufmann, MD, Johann Wolfgang Goethe University Hospital, Department of Dermatology and Venereology, Theodor-Stern-Kai 7, Frankfurt am Main, Germany. kaufmann@em.uni-frankfurt.de /$30.00 Ó 2004 American Academy of Allergy, Asthma and Immunology doi: /j.jaci were sustained during the open-label phase, and pimecrolimus cream 1% was well tolerated. Symptoms of atopic eczema returned gradually after discontinuation. Conclusion: Pimecrolimus cream 1% was well tolerated and effective in patients with mild to very severe atopic eczema, with rapid onset of action and no disease rebound after discontinuation. (J Allergy Clin Immunol 2004;114: ) Key words: Pimecrolimus, infants, atopic eczema, dermatitis Atopic eczema (also known as atopic dermatitis) is a common skin disorder affecting 10% to 15% of children less than 5 years of age in Western countries. 1 Approximately 48% to 75% of these individuals present with signs and symptoms of the disease during the first 6 months of life. 2,3 Poor control of atopic eczema during early life is not simply a burden for patients and their caregivers but is also associated with an increased risk of persistent disease in later childhood and adulthood 4 and the development of other atopic diseases, such as asthma and allergic rhinitis. Traditional management of atopic eczema in infants and young children consists of the exclusion of atopic triggers and irritants from the child s environment, the use of emollients to maintain skin hydration, and the use of topical corticosteroids to treat flares. 5,6 This approach is deficient because topical corticosteroids can only be used for a limited period without risking local adverse reactions, most importantly skin atrophy. 7-9 In infants and young children there is also a higher body surface area/weight ratio and therefore a greater risk of adverse systemic effects with extensive corticosteroid use, such as suppression of the hypothalamic-pituitary-adrenal axis Pimecrolimus is a nonsteroid inhibitor of inflammatory cytokines formulated as a 1% cream for the treatment of atopic eczema and other inflammatory skin diseases. 13 Pimecrolimus works by selectively inhibiting the expression of inflammatory cytokines by inflammatory T cells and preventing the release of proinflammatory mediators by mast cells As a consequence of this selective mode of action, pimecrolimus cream 1% (Elidel) does not cause skin atrophy or other local, steroid-like adverse effects and has no significant systemic effects. 15,17 Prevention of flares and effective long-term control of atopic eczema were demonstrated in 3 large, multicenter, controlled studies with pimecrolimus cream 1% However, in previous studies the first postbaseline assessment was performed only after 1 week, and hence 1183
2 1184 Kaufmann et al J ALLERGY CLIN IMMUNOL NOVEMBER 2004 Abbreviations used EASI: Eczema Area and Severity Index IGA: Investigators Global Assessment data on the efficacy of pimecrolimus cream 1% within the first days of treatment are scarce. Acute atopic eczema is usually associated with bothersome itching and sleep disturbances, which can lead to an impaired well-being and decreased quality of life for patients and their caregivers. 4 In this situation the doctor is expected to prescribe drugs that provide rapid itch relief. Here we present the results of a multicenter, vehiclecontrolled study of the efficacy and safety of pimecrolimus cream 1% in infants with mild to very severe atopic eczema, with the primary objective being the assessment of the speed of response within the first days of treatment. METHODS Study design This was a 20-week, randomized, controlled, multicenter study, comprising 3 phases. The first was a double-blind, vehicle-controlled, parallel-group phase, during which patients were randomly assigned 2:1 to receive either pimecrolimus cream 1% or vehicle equivalent for 4 weeks. This phase was followed by a 12-week open-label extension phase, during which all patients received pimecrolimus cream 1%. Patients could be switched to open-label pimecrolimus cream 1% treatment after 2 weeks of the double-blind phase if they achieved total disease clearance or if they did not show any improvement. The third phase was a 4-week follow-up period in which active treatment was discontinued in all patients to enable the return of symptoms to be assessed. The study design was approved by the participating hospitals institutional review boards and was conducted according to the Declaration of Helsinki and the standards of Good Clinical Practice. 21 Patients The study included pediatric patients aged 3 to 23 months with a clear diagnosis of atopic eczema 22 affecting 5% or more of the body surface area and with a baseline Investigators Global Assessment (IGA) score of 2 (mild disease severity) or greater on the basis of the degree of erythema and infiltration-papulation. Eligible patients also had atopic eczema affecting the face. Patients with insufficient washout periods (ie, <1 month for systemic corticosteroids and phototherapy, <2 weeks for antibiotics, and <1 week for topical steroids or other topical therapies that might have an effect on atopic eczema) were excluded. Patients with concomitant diseases that might have interfered with the study, including severe concurrent skin disease in the study area and active viral or bacterial infections, were also excluded. Other excluded groups were immunocompromised patients or those with a known hypersensitivity to the study drug. Written informed consent by the patient s legal guardian was required. The study was conducted between June 2001 and July 2002 at a total of 19 centers in Germany. Treatment Primary caregivers were instructed to apply pimecrolimus cream 1% or the corresponding vehicle equivalent to the patient twice daily during the double-blind phase. Applications were made approximately 12 hours apart (typically 8 AM and 8 PM) as a thin film on all areas affected by atopic eczema. Unaffected areas or previously affected skin areas that were clear of disease were not treated with the study medication. During the 4-week double-blind phase, emollients were only applied to areas not treated with study medication. However, during the 12-week open-label phase and the 4-week discontinuation phase, the use of emollients was permitted, as required, on all body areas. Application onto treated areas was allowed only after the study medication had been fully absorbed. Assessments The primary efficacy parameter was the Eczema Area and Severity Index (EASI). 23 This is a validated tool for objectively assessing the severity of eczema, taking into account both the severity of symptoms and surface area involvement. 24 It assesses erythema, infiltrationpapulation, excoriation, and lichenification separately in the head and neck region, trunk, upper limbs, and lower limbs. Proportionate values are assigned to each of these 4 body regions, and the figures are combined to yield an overall EASI score ranging from 0 (no disease present) to 72 (all signs of disease rated severe and present over 100% of body surface). The severity of disease was also assessed with the IGA, a 6-point scale from 0 (clear) to 5 (very severe disease). 25 This scale measures disease severity on the basis of morphology, without reference to the baseline state. The IGA also enabled the proportion of patients with a severe flare, defined by an IGA score of 4 or 5 (severe or very severe disease), to be determined at each assessment. The patient s primary caregiver was asked to assess the degree of disease control over the previous 7 days by using a 4-point scale from 0 (complete disease control) to 3 (uncontrolled disease). Caregivers also assessed both pruritus and sleep loss in a daily diary, using visual analog scales of 0 to 10, as specified in the Severity Scoring of Atopic Dermatitis (SCORAD) assessment tool for atopic eczema. 26,27 Adverse events were monitored and recorded throughout the study, together with regular measurement of vital signs and physical examinations. Blinding and statistical analysis Patients were assigned to treatment according to a computergenerated blinded randomization list. The double-blind status of the initial phase of the study was maintained by the use of study medication and vehicle of identical appearance and odor. Efficacy was analyzed in the intention-to-treat population by using the lastobservation-carried-forward method for patients who discontinued participation. The primary efficacy variable was the change in EASI at end point, defined as the end of the double-blind treatment phase or the last postbaseline assessment in the case of early discontinuation. The primary statistical null hypothesis (ie, no differences in changes in EASI between the pimecrolimus cream 1% and vehicle control treatment groups) was performed with an adjusted analysis of covariance model. The baseline for changes in pruritus and sleep loss was the last day before commencing treatment with study medication. Safety was assessed by comparing the incidence of adverse events between the treatment groups. A time-to-event analysis was performed to determine the adjusted incidence of adverse events to account for the difference in duration of followup in the 2 treatment groups. RESULTS Patients In total, 201 patients were included in the study at 19 centers; 196 of these patients were allocated to randomized treatment, 130 with pimecrolimus cream 1%
3 J ALLERGY CLIN IMMUNOL VOLUME 114, NUMBER 5 Kaufmann et al 1185 TABLE I. Baseline demographics and disease characteristics Pimecrolimus cream 1% (n = 129) Vehicle (n = 66) Age, mo (mean 6 SD) Sex, n (%) Male 81 (62.8) 47 (71.2) Female 48 (37.2) 19 (28.8) Ethnicity, n (%) White 117 (90.7) 61 (92.4) Black 2 (1.6) 0 (0) Asian 7 (5.4) 4 (6.1) Other 3 (2.3) 1 (1.5) Height, cm (mean 6 SD) Weight, kg (mean 6 SD) IGA score, n (%) 2 (Mild) 12 (9.3) 8 (12.1) 3 (Moderate) 75 (58.1) 39 (59.1) 4 (Severe) 34 (26.4) 17 (25.8) 5 (Very severe disease) 8 (6.2) 2 (3.0) EASI score (mean 6 SD) and 66 with vehicle. The patients progression through the successive phases of the study is summarized in Fig E1 in the Journal s Online Repository at One hundred seventeen (90%) patients from the pimecrolimus group and 41 (62.1%) patients from the vehicle group completed the double-blind phase. One hundred eighty-eight patients entered the open-label phase, and 162 entered the follow-up phase. The baseline demographic and clinical characteristics in the intention-to-treat population are summarized in Table I. Efficacy Double-blind phase. Pimecrolimus cream 1% was effective and fast acting in reducing the signs and symptoms of atopic eczema during the double-blind phase. The mean 6 SD EASI score decreased by 71.5% (from at baseline to at day 29) in the pimecrolimus group but increased by 19.4% (from to ) in the vehicle group (P<.001) at the end of week 4. The response to pimecrolimus cream 1% treatment was rapid, with a reduction of 6.5 points, or 38.5%, in mean EASI score by day 4 (the first ontreatment visit) compared with an increase of 1.8 points, or 17.6%, in the vehicle group (P <.001). The treatment difference between the 2 groups continued to increase throughout the double-blind phase of the study (Fig 1). Pimecrolimus cream 1% was highly effective in patients with severe atopic eczema. Patients with severe baseline disease (IGA 4) experienced a statistically significant mean reduction in EASI score compared with vehicle of 74.7% (from to ) over the course of the double-blind phase (P <.001). Similar responses were observed in patients with mild or moderate baseline disease (IGA 3), who had a mean decrease of 70% in EASI score (from to , P<.001, Fig 2) at the end of week 4. FIG 1. Improvement in clinical symptoms of atopic eczema as assessed by EASI score during the double-blind and open-label phases. When the response to treatment was assessed in the head and neck region alone, the rate and overall magnitude of the response, as measured on the basis of the EASI score, were similar to those observed for the body as a whole. In the pimecrolimus group the mean EASI score for the head and neck decreased by 40.1% (from at baseline to ) at day 4 and was reduced by 73.1% to a mean score of at day 29. In contrast, in the vehicle group the mean EASI score increased by 34.7% (from at baseline to ) by day 29. Marked improvements in the overall severity of disease were also observed in terms of IGA score. Treatment success (IGA = 0 [clear] or IGA = 1 [almost clear]) was achieved by 69 (53.5%) patients in the pimecrolimus group at day 29 compared with 7 (10.6%) patients treated with vehicle (P<.001 for the between-group comparison, Cochran-Mantel-Haenszel test). In the pimecrolimus group 42 (32.6%) patients had a severe flare (as defined by an IGA score of 4 or 5) at baseline, but this decreased to 10 (7.7%) patients by day 4 and 7 (5.5%) patients by day 8 and remained less than 5% at days 15 and 29. In contrast, 19 (28.8%) patients in the vehicle group had a flare at baseline, and this figure remained greater than 30% in all postbaseline assessments. The primary caregivers assessment of disease response was similar to that of physicians. At day 29, disease control was assessed by primary caregivers to be good or complete in 104 (80.6%) patients in the pimecrolimus group and in 15 (22.7%) patients in the vehicle group (P<.001). As assessed by primary caregivers, pruritus and sleep loss in patients also showed rapid and substantial improvement after treatment with pimecrolimus cream 1%. In the pimecrolimus group the mean pruritus score decreased from at baseline to at day 29, whereas in the vehicle group it increased from at baseline to at day 29 (P <.001 for the between-group comparison, Fisher exact test). Similarly, the mean sleep-loss score decreased from to in the pimecrolimus group but increased from to by day 29 in the vehicle group (P<.001 for the between-group comparison, Fisher exact test).
4 1186 Kaufmann et al J ALLERGY CLIN IMMUNOL NOVEMBER 2004 FIG 3. Percentage of patients with an improvement of at least 50% from baseline according to the primary caregiver s assessment (visual analog scale). A, Pruritus. B, Sleep loss. FIG 2. Improvement in clinical symptoms of atopic eczema in patients treated with pimecrolimus cream 1% during the doubleblind phase. Mean total EASI score in patients with mild or moderate disease (IGA = 2-3; A) compared with that seen in patients with severe or very severe disease (IGA = 4-5; B). The percentage of patients with an improvement in pruritus and sleep-loss scores from baseline of at least 50% increased rapidly with pimecrolimus cream 1% treatment, with a statistically significant pruritus treatment effect in favor of pimecrolimus cream 1% by day 2 and a significant improvement in sleep loss by day 3 (P<.001, Fig 3). From day 4 on, more than 60% of patients treated with pimecrolimus cream 1% had an improvement from baseline in pruritus and sleep-loss scores of at least 50%. In contrast, less than 15% of patients treated with vehicle had an improvement in pruritus score of 50% or greater and less than 30% in terms of sleep loss after day 4 (Fig 3). Open-label extension phase. The significant improvements in atopic eczema observed in the pimecrolimus group during the double-blind phase were sustained throughout the 12 weeks of open-label treatment. By the end of the open-label phase, disease severity in this group had improved to the same degree as in the group that had received pimecrolimus cream 1% in both treatment phases (Fig 1). Follow-up phase. The final 4-week follow-up phase began after the discontinuation of pimecrolimus cream 1% treatment in all patients. During this phase, there was a gradual increase in the severity of atopic eczema. After 2 weeks without active treatment, the mean EASI score increased from at the end of the open-label phase to When 4 weeks without active treatment had elapsed, a further slight deterioration in the signs and symptoms of atopic eczema occurred, and the mean EASI score increased to This represented a much lower disease severity than at study baseline, where the mean EASI score for the population that entered the follow-up phase was Safety Double-blind phase. A total of 83 (63.8%) patients in the pimecrolimus group and 40 (60.6%) patients in the vehicle group experienced at least one adverse event during the double-blind phase. Most of the adverse events in both groups were mild to moderate in severity. Three (2.3%) patients in the pimecrolimus group and 2 (3.0%) patients in the vehicle group experienced a treatmentrelated adverse event. These were application-site burning (1 patient in each treatment group), impaired healing (1 patient in the pimecrolimus group), burning sensation (1 patient in the pimecrolimus group), and erythema (1 patient in the vehicle group). In addition, 2 (1.5%) patients from the pimecrolimus group and 1 (1.5%) patient from the vehicle group experienced a treatment-related serious adverse event resulting in discontinuation from the study. One discontinuation from each group was due to a superinfection (together with aggravated atopic eczema in the vehicle group), and the third patient had a moderate case of eczema herpeticum. The most common adverse events in both groups were typical childhood ailments (Table II). After correcting for the length of time in the study, there was no overall difference in the occurrences of these common ailments between the 2 treatment groups. Local tolerability of pimecrolimus cream 1% was excellent. Parents reports of application-site burning were very uncommon, occurring in only one patient in each group. There were no clinically significant differences between the groups in the occurrence of any skin infections or infestations. Open-label and follow-up phases. During the openlabel phase, 138 (73.4%) patients experienced at least one
5 J ALLERGY CLIN IMMUNOL VOLUME 114, NUMBER 5 Kaufmann et al 1187 adverse event. Most of these were mild to moderate in severity, and almost all (132/138 patients) were considered unrelated to the study drug and to be common childhood ailments (as in the double-blind phase). A total of 9 patients had severe adverse events; 6 patients had a suspected treatment-related adverse event, including 4 cases of infection (2 cases of impetigo, 1 of herpes simplex dermatitis, and 1 of varicella) and one case each of asthma, aggravated atopic eczema, and exacerbated eczema. Three patients discontinued the study because of adverse events (teething, pyrexia, and rash). Local tolerability of pimecrolimus cream 1% was excellent, with only one patient experiencing a mild burning sensation. TABLE II. Adjusted incidence rates of common adverse events ($5% for any group) in the double-blind phase Adverse event Pimecrolimus cream 1%, (n = 130), % Vehicle (n = 66), % P value Nasopharyngitis Pyrexia Rhinitis NOS Diarrhea NOS Cough Bronchitis NOS Contact dermatitis Gastroenteritis NOS NOS, Not otherwise specified. Discussion This study has demonstrated that pimecrolimus cream 1% is highly effective and has a good safety profile in the treatment of atopic eczema of all severities in infants aged 3 to 23 months. A rapid response was observed, with a statistically significant treatment difference in EASI score emerging between the pimecrolimus and vehicle groups from day 4 on (the first on-treatment visit), when a decrease of almost 40% in the clinical symptom score could already be observed. Most of the full treatment effect was achieved by day 8, after which the level of improvement was sustained. The improvement in EASI score was confirmed by other assessments, including IGA and caregivers assessment. The response to pimecrolimus cream 1% was sustained during the 12 weeks of open-label therapy, and patients who had received vehicle during the double-blind phase rapidly achieved a comparable level of response when switched to open-label pimecrolimus cream 1%. 25,28 An important finding of the study was that pimecrolimus cream 1% was at least as effective in patients with severe and very severe disease as it was in patients with milder disease. Approximately 30% of patients in each treatment group had an IGA score at baseline of 4 or 5, corresponding to severe or very severe disease, and these patients had a greater absolute reduction in EASI score than patients with mild or moderate disease during the course of the study. However, the improvement, when expressed as a percentage of baseline EASI score, was comparable for patients of all baseline disease severities. The rate of improvement in terms of pruritus and patient sleep loss, as assessed by caregivers, was even more rapid than the improvement in EASI score. Sleep loss (caused by pruritus) has been shown to be very common when a child is experiencing a flare of atopic eczema, 29 and rapid alleviation of pruritus can have significant effects on the quality of life of both the child and the caregiver. Statistically significant differences between the pimecrolimus and vehicle groups in the percentage of patients with at least a 50% improvement from baseline were observed as early as day 2 for pruritus and day 3 for sleep loss. As with the EASI score, the full benefits of treatment were largely achieved within 1 week and sustained thereafter. An important issue addressed by this study was the possibility of disease rebound after discontinuation of active treatment. The effects of treatment cessation were investigated in the final 4-week phase of the study, during which no active treatment was given. During this phase, there was a gradual increase in the signs and symptoms of atopic eczema; however, by the end of the study period, the overall severity of disease remained considerably lower than at study baseline. Disease rebound can occur after topical corticosteroids are discontinued 7 and hence can compromise corticosteroid-based management because indefinite treatment with steroids to maintain disease control is not a safe option. In contrast, pimecrolimus cream 1% maintains a good safety profile when used for extended periods and, as shown by this study, can be discontinued when clinically appropriate, without any risk of disease rebound. Treatment with pimecrolimus cream 1% was well tolerated throughout the course of the study. All the common adverse events recorded during the study were typical childhood ailments, none of which were considered by investigating physicians to be related to treatment, and after correction for time on the study, the incidence of side effects was no higher with pimecrolimus cream 1% than with vehicle. The discontinuation rate during the double-blind phase was higher in the vehicle group (37.9%) than in the pimecrolimus group, in which only 10.4% of patients discontinued treatment early. Local skin infections occurred at similar frequencies in the pimecrolimus cream 1% and vehicle groups, and there was no evidence of skin atrophy, which is consistent with the nonsteroid mode of action of pimecrolimus. In conclusion, pimecrolimus cream 1%, given twice daily, is an effective and well-tolerated treatment for controlling atopic eczema of all severities in infants aged 3 to 23 months. The response is rapid, with clinically significant improvements in pruritus and the clinical signs of atopic eczema evident within 2 and 3 days, respectively, compared with vehicle. Sleep loss is also rapidly improved. Pimecrolimus cream 1% retains its clinical effectiveness in long-term use, and there is no rebound effect when it is discontinued. These findings suggest that
6 1188 Kaufmann et al J ALLERGY CLIN IMMUNOL NOVEMBER 2004 the treatment of atopic eczema with pimecrolimus cream 1% constitutes an important advance in the management of this disease in infants. We thank the following investigators: Ulrich Wahn, Christiane Bayerl, Martin Hartmann, Andrea von Berg, Alexander Kapp, Hans Merk, Michael Meurer, Uwe Schauer, Johannes Forster, Klaus Deichmann, Michael Sebastian, Wolfgang Kamin, Volker Wahn, Rüdiger Szczepanski, Frank Friedrichs, Heidelore Hofmann, Udo Amann, and Margarita Meisel-Stosiek. Additional thanks are also extended to Stefan Bruns, Kathrin Krüger-Barvels Sabine Nowak, Sabine Stegner, and Doris Weber for their assistance with study administration and statistical analysis. REFERENCES 1. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy 1993;31: Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994;30: Wadonda N, Golding J, Kennedy C, et al. Prevalence of atopic eczema in children between 0 and 30 months on Avon district. Br J Dermatol 2000; 143(suppl 57): Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112(suppl):S Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003;112(suppl):S Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000;39: Gunther S. [Incidence and degree of unwanted adverse effects of corticoids in childhood: results of dermatological studies in children with chronic diseases in the age group of 1-15 years]. Z Hautkr 1976;51: Hill CJ, Rostenberg A Jr. Adverse effects from topical steroids. Cutis 1978;21: McLean CJ, Lobo RF, Brazier DJ. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345: Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1: Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing s syndrome after topical application of corticosteroids. Am J Dis Child 1982;136: Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA 1980;244: Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137: Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290: Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141: Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108: Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144: Wahn U, Bos J, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110: Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205: Administration UFaD. Guidance for Industry. E6 good clinical practice: consolidated guidance. Federal Register 1997;62: Seymour JL, Keswick BH, Hanifin JM, Jordan WP, Milligan MC. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol 1987;17: Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10: Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% clinical program. Br J Dermatol 2004;150: Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46: Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186: Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195: Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142: Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol 1995;20:38-41.
A topic dermatitis is an itching inflammatory skin
969 ORIGINAL ARTICLE Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients B R Allen, M Lakhanpaul, A Morris, S Lateo, T Davies, G Scott, M Cardno, M-E Ebelin,
More informationSafety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years
REVIEW ARTICLE Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years Carle Paul, MD, PhD a, Michael Cork, PhD, FRCP b, Ana B. Rossi, MD
More informationCite this article as: BMJ, doi: /bmj d3 (published 24 February 2005)
Cite this article as: BMJ, doi:10.1136/bmj.38376.439653.d3 (published 24 February 2005) Primary care Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis:
More informationPimecrolimus A Safe and Effective Local Immunomodulator in the Treatment of Inflammatory Skin Diseases
2005;13(1):63-69 REVIEW Pimecrolimus A Safe and Effective Local Immunomodulator in the Treatment of Inflammatory Skin Diseases Jasna Lipozenčić University Department of Dermatology and Venereology, Zagreb
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPimecrolimus in dermatology: atopic dermatitis and beyond
DRUG FOCUS doi: 10.1111/j.1368-5031.2005.00587.x Pimecrolimus in dermatology: atopic dermatitis and beyond PAOLO GISONDI, 1 CHARLES N. ELLIS, 2 GIAMPIERO GIROLOMONI 3 Department of Dermatology, 1 Istituto
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSTUDY. 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis
STUDY 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis A Double-blind, Randomized Controlled Study Alexander Kreuter, MD; Anna Sommer, MD; Julia
More informationAtopic dermatitis (AD), which can produce
Original Article 485 Efficacy and Safety of Topically Applied Tacrolimus Ointment in Patients with Moderate to Severe Atopic Dermatitis Wen-Rou Wong, MD; Hsiang-Ju Tsai, MD; Hong-Shang Hong, MD, PhD Background:
More informationCiclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong
ORIGINAL ARTICLES Ciclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong Drs. H. F. Ho, L.Y. Chong, K. M. Ho and W. K. Fung Social Hygiene Service (Dermatology),
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More information资料来自互联网, 仅供科研和教学使用, 使用者请于 24 小时内自行删除
Clinical dermatology Original article CED Clinical and Experimental Dermatology A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea:
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationEFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Platonova et al. SJIF Impact Factor 2.786 Volume 4, Issue 04, 238-246. Research Article ISSN 2278 4357 EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationCore Safety Profile. AT/H/PSUR/0013/002 Date of FAR:
ore afety Profile Active substance: Methylprednisolon aceponate Pharmaceutical form(s)/strength: ream / 0.1 % Fatty ointment / 0.1 % utaneous emulsion / 0.1 % intment / 0.1 % utaneous solution / 0.1 %
More informationAtopic Dermatitis Guidelines: What s New?
Atopic Dermatitis Guidelines: What s New? Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Anacor/Pfizer Genentech
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: , VERSION 12.0
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: 23.11.2016, VERSION 12.0 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Eczema mainly affects children
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationSTUDY. Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis
STUDY Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis Sakari Reitamo, MD; Andreas Wollenberg, MD; Erwin Schöpf, MD; Jean Luc Perrot, MD; Ronald Marks,
More informationRunning head: ATOPIC DERMATITIS, ITS IMPACT AND TREATMENT
Atopic Dermatitis, Its Impact and Treatment Running head: ATOPIC DERMATITIS, ITS IMPACT AND TREATMENT The Impact of Treatment on Quality of Life of Children with Atopic Dermatitis and their Families Consuela
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationNew Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003
New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal
More informationPRODUCT MONOGRAPH. Pr ELIDEL* (Pimecrolimus) Cream, 1% Topical Calcineurin Inhibitor
PRODUCT MONOGRAPH Pr (Pimecrolimus), % Topical Calcineurin Inhibitor Valeant Canada LP / Valeant Canada S E C 77 Levy Street Montreal, Quebec HR P9 Date of Preparation: November, Control No. * is a registered
More informationTopical Doxepin Prior Authorization with Quantity Limit Program Summary
Topical Doxepin Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-3 Agent(s) Indication(s) Dosage & Administration Doxepin 5% cream Prudoxin (doxepin) cream 5% KS_PS_Topical_Doxepin_PAQL_ProgSum_AR1018
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
More informationPsoriasis is a lifelong condition, with onset
THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More informationTOPCORT Cream/Ointment (Mometasone furoate 0.1%)
Published on: 10 Jul 2014 TOPCORT Cream/Ointment (Mometasone furoate 0.1%) Composition TOPCORT Cream Mometasone Furoate, IP... 0.1% w/w In a cream base... q.s. TOPCORT Ointment Mometasone Furoate, IP...
More informationMarch 9, 2015 From: The Pediatric Dermatology Research Alliance (PeDRA)
Web: www.pedraresearch.org From: The Pediatric Dermatology Research Alliance (PeDRA) To: Jennifer Shepherd, Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Ave.,
More informationEfficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study
Ann Dermatol Vol. 26, No. 4, 2014 http://dx.doi.org/10.5021/ad.2014.26.4.462 ORIGINAL ARTICLE Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR:
0BCore Safety Profile Active substance: Pimecrolimus Pharmaceutical form(s)/strength: Cream 1% P-RMS: DK/H/PSUR/0009/005 Date of FAR: 06.06.2013 4.3 Contraindications Hypersensitivity to pimecrolimus,
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationMETHYLPREDNISOLONE ACEPONATE (MPA)
RE AFETY PRFILE ETHYLPREDNILNE AEPNATE (PA) 4.2 Posology and method of administration PA is to be applied thinly once daily to the affected areas and rubbed in lightly. PA cream/ointment/fatty ointment:
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationSCORAD and PO-SCORAD
SCORAD and PO-SCORAD Tools for assessing atopic eczema MetteDeleuran Department of Dermatology Aarhus University Hospital, Denmark SCORAD and PO-SCORAD Tools for assessing atopic eczema SCORAD: The doctors
More informationReceived: June 29, 2006 Revised: August 15, 2006 Accepted: August 30, 2006
Quality J Microbiol of life Immunol in atopic Infect. dermatitis patients 7;4:6-64 Quality of life in atopic dermatitis patients Original Article Habibeh Mozaffari, Zahra Pourpak,, Sara Pourseyed, Abolhasan
More informationAtopic dermatitis (AD) is a recurrent inflammatory
Tacrolimus Ointment 0.03% Is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study Lawrence
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ovixan 1 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram cream contains 1 mg mometasone furoate Excipients with known
More informationNEW ZEALAND DATA SHEET
EUMOVATE Cream NEW ZEALAND DATA SHEET Name of each active ingredient Clobetasone 17-Butyrate BP 0.05% w/w Presentations Eumovate Cream is white in appearance and contains 0.05% w/w clobetasone butyrate.
More informationTechnology appraisal guidance Published: 25 August 2004 nice.org.uk/guidance/ta82
Tacrolimus and pimecrolimus for atopic eczema Technology appraisal guidance Published: 25 August 2004 nice.org.uk/guidance/ta82 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Topical Doxepin Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin (For Individuals Who Purchased BlueCare/KS Solutions/EPO Products) Prime
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Protopic 0.03% ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of Protopic 0.03% ointment contains 0.3 mg of tacrolimus
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Psoriasis (excluding widespread plaque psoriasis) Psoriasis is a common chronic skin disorder. Estimates of the prevalence (proportion
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationAtopic Dermatitis. Atopic dermatitis (AD) is very common with a. Going Skin Deep With. Carl s rashes
Focus on CME at Dalhousie University Going Skin Deep With Atopic Dermatitis Scott Murray, MD, FRCP(C), BSc Atopic dermatitis (AD) is very common with a tendency for itching and inflammation of the skin.
More informationHong Kong Academy of Medicine. Understanding Steroids: Appropriate usage under close monitoring is beneficial
Press Release Hong Kong Academy of Medicine Understanding Steroids: Appropriate usage under close monitoring is beneficial (Hong Kong, November 21, 2012) Steroid, by suppressing inflammatory response,
More informationGlenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
More informationDermatitis (inflammatory skin condition) Nonallergic. dermatitis. Non-atopic eczema (non- IgE mediated)
Atopic Eczema Dermatitis (inflammatory skin condition) Allergic dermatitis -eczema Nonallergic dermatitis Atopic eczema (IgE mediated) Non-atopic eczema (non- IgE mediated) Pathophysiology of Eczema Allergy
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory EUMOSONE. Clobetasone Cream IP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory EUMOSONE Clobetasone Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION EUMOSONE contains : Clobetasone Butyrate IP 0.05
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Elidel 10 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of cream contains 10 mg of pimecrolimus. For a full list of excipients,
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationPRESCRIBING INFORMATION. Cream 0.025% Topical Corticosteroid
PRESCRIBING INFORMATION Pr PROPADERM (beclomethasone dipropionate) Cream 0.025% Topical Corticosteroid Valeant Canada LP 2150 St-Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8 Date of preparation: October
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Topical Doxepin Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationPRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION. Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.
PRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION NAME OF THE MEDICINE Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.05% w/w) Chemical Structure: Betamethasone dipropionate
More informationEfficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis Sakari Reitamo, MD, a Edwin J. M. Van Leent, MD, b Vincent Ho, MD, c
More informationDATA SHEET. Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
DATA SHEET 1. DIPROSONE DIPROSONE (0.05% w/w) cream DIPROSONE (0.05% w/w) ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
More informationCORTISPORIN Ointment (neomycin and polymyxin B sulfates, bacitracin zinc, and. hydrocortisone ointment, USP)
CORTISPORIN Ointment (neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone ointment, USP) DESCRIPTION CORTISPORIN Ointment (neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone
More informationClinical Study Report Synopsis
Clinical Study Report Synopsis An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis Design of trial: Single-centre,
More informationPaediatric Food Allergy. Introduction to the Causes and Management
Paediatric Food Allergy Introduction to the Causes and Management Allergic Reactions in Children Prevalence of atopic disorders in urbanized societies has increased significantly over the past several
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect Cetyl alcohol For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Haelan Ointment Fludroxycortide 0.0125% w/w Ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fludroxycortide 0.0125% w/w. Excipient
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Tacrolimus 0.1% Ointment Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g ointment contains tacrolimus monohydrate corresponding to 1.0
More informationDIPROSONE OV Cream and Ointment do not contain preservatives, parabens or lanolin.
PRODUCT INFORMATION DIPROSONE OV (OPTIMISED VEHICLE) CREAM AND OINTMENT NAME OF THE MEDICINE DIPROSONE OV Cream and Ointment (Betamethasone dipropionate) Chemistry Abstracts Service (CAS) registry number:
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationDermatology Literary Review
Emollients and ageing skin: optimising effectiveness and safety of Nursing, Vol. 25, No.11, pages 596-598. 6 Article outlines the causes of dryness in ageing skin and concludes that emollients are the
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationCordran Cream and Cordran Ointment Flurandrenolide, USP
Cordran Cream and Cordran Ointment Flurandrenolide, USP DESCRIPTION Cordran (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy,
More informationElocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile
Elocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile 4.3 Contraindications Elocon is contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis,
More informationAtopic dermatitis (AD) is a chronic or relapsing skin disease
Formulary Management Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationHYDROCORTISONE OINTMENT USP,
HYDROCORTISONE- hydrocortisone ointment E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- HYDROCORTISONE OINTMENT USP, 1% Rx only For External Us e Only Not For Ophthalmic Us e DESCRIPTION:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the Medicinal Product Eumovate Cream 2. Qualitative and Quantitative Composition 0.05% w/w clobetasone butyrate. Excipients with known effect: Cetostearyl
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET DERMOL 1. Product Name Dermol, 0.05% w/w, scalp lotion. 2. Qualitative and Quantitative Composition Each 1 g of scalp lotion contains 0.5 mg of clobetasol propionate. For the full
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope November 7, 2016 Background: Atopic dermatitis (eczema) is a chronic/chronically-relapsing
More informationEczema. By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University
Eczema By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University Dermatitis= Eczema =Spongiosis Eczema Atopic Seborrheic Contact Allergic Irritant Nummular Asteatotic Stasis Neurodermatitis/Lichen Simplex
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationEfficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept
Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept Robert Bissonnette, MD, FRCPC, a Chantal Bolduc, MD, FRCPC, a Yves Poulin, MD,
More informationItchy babies: Current treatment guidelines for atopic dermatitis
Itchy babies: Current treatment guidelines for atopic dermatitis Rachel Laarman, MD Helen DeVos Children s Hospital Grand Rapids, MI Photo cred: www.dermatologytimes.modernmedicine.com I have no disclosures
More information15 minute eczema consultation
THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN
RELEVANT DISCLOSURES MANAGING ECZEMA IN INFANTS AND CHILDREN Advisory board member - MEDA (Elidel), Speaking honoraria Bayer (Advantan) Advisory board, consultant, speaker: Pfizer, Abbvie, Janssen, Elli
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More information